Kidney Cancer Research Results and Study Updates
See Advances in Kidney Cancer Research for an overview of recent findings and progress, plus ongoing projects supported by NCI.
SBRT Emerging as an Important Treatment for Early-Stage Kidney CancerPosted:
Stereotactic body radiotherapy was effective in people with localized kidney cancer who weren’t able to have surgery to remove their tumor, a clinical trial has shown. No patients had their cancer start growing or died from cancer over the next 5 years.
Belzutifan Approved to Treat Tumors Linked to Inherited Disorder VHLPosted:
FDA has approved belzutifan (Welireg) to treat adults with von Hippel-Lindau disease (VHL) who have tumors of the kidney, brain, nervous system, or pancreas. The drug may help these patients avoid or delay surgery by shrinking their tumors.
Targeted Therapy Cabozantinib Slows Progression of Rare Kidney CancerPosted:
Cabozantinib (Cabometyx) is an effective initial treatment for people with metastatic papillary renal cell carcinoma (PRCC), a rare type of kidney cancer. A clinical trial showed the drug was more effective than the current standard treatment.
Liquid Biopsy Detects Brain Cancer and Early-Stage Kidney CancerPosted:
Results from two studies show that a liquid biopsy that analyzes DNA in blood accurately detected kidney cancer at early and more advanced stages and identified and classified different types of brain tumors.
Targeted Therapy–Immunotherapy Combinations Effective for Advanced Kidney CancerPosted:
In two clinical trials, combination treatments that included an immune checkpoint inhibitor and axitinib (Inlyta) led to better outcomes for patients with advanced kidney cancer than treatment with sunitinib (Sutent), the standard initial therapy.
Some Children with Wilms Tumor Can Receive Less Therapy, Study SuggestsPosted:
Results from an NCI-sponsored clinical trial may point to an important change in how some children with advanced Wilms tumor, a form of kidney cancer, are treated.
FDA Approves Nivolumab and Ipilimumab Combination for Advanced Kidney CancerPosted:
FDA has approved the combination of two immunotherapy drugs, nivolumab (Opdivo) and ipilimumab (Yervoy), as an initial treatment for some patients with advanced kidney cancer. Learn how this approval will affect patient care.
Cabozantinib Approval Expands Initial Treatment Options for Advanced Kidney CancerPosted:
The Food and Drug Administration has approved cabozantinib (Cabometyx®) as an initial treatment for patients with advanced renal cell carcinoma, the most common type of kidney cancer.
Studies Highlight Potential of Targeting HIF-2 in Kidney CancerPosted:
Two new studies suggest that a new class of drugs can effectively target a molecular driver of the most common type of kidney cancer.
Two New Therapies Approved by FDA for Advanced Kidney CancerPosted:
The FDA has approved two drugs, cabozantinib and lenvatinib, for patients whose advanced kidney cancers have progressed after prior treatment with antiangiogenic therapies.
Sunitinib and Sorafenib Ineffective as Adjuvant Therapies for Kidney CancerPosted:
Results from a recent clinical trial show that post-surgical therapy with two anti-angiogenesis drugs does not improve progression-free survival for patients with kidney cancer and may cause serious side effects.
TCGA findings on papillary renal cell carcinoma and prostate cancerPosted:
Researchers with The Cancer Genome Atlas (TCGA) report new findings on papillary renal cell carcinoma and prostate cancer.